Tevogen announces Tevogen Generics following Trump’s tariff-related statements

Tevogen (TVGN) announced its newest effort: Tevogen Generics. “This effort is in response to the growing national focus on pharmaceutical affordability and coincides with the recent tariff-related statements from President Donald Trump,” the company said. To lead the launch of Tevogen Generics, the company has expended responsibilities of its Chief Commercial Officer, Sadiq Khan, to include Interim Head of this new effort. The company noted that Tevogen Generics now stands as the third strategic pillar of Tevogen Bio Holdings, joining Tevogen Bio – specialty immunotherapy biotech pioneering off-the-shelf, precision T cell therapies; Tevogen.AI – leveraging artificial intelligence to accelerate drug discovery and streamline healthcare delivery; and Tevogen Generics – dedicated to making high-quality, essential medicines accessible to all.